4.6 Review

Challenges in the analysis of epigenetic biomarkers in clinical samples

期刊

CLINICAL CHEMISTRY AND LABORATORY MEDICINE
卷 55, 期 10, 页码 1474-1477

出版社

WALTER DE GRUYTER GMBH
DOI: 10.1515/cclm-2016-1162

关键词

ChIP assay; DNA methylation; formalin-fixed paraffin-embedded (FFPE); liquid biopsy; microRNAs (miRNAs)

资金

  1. AES (ISCIII) [PI16/01036]
  2. Generalitat Valenciana [GV2016-109]
  3. Regional Ministry of Education, Research, Culture and Sport (Valencia) [APOSTD/2016/140]

向作者/读者索取更多资源

Epigenetic modifications represent an interesting landscape which can describe relevant features of human disease. Epigenetic biomarkers show several advantages as disease biomarkers because they provide information about gene function, specific endophenotypes and can even incorporate information from the environment and the natural history of disease. The improvement in genomic and epigenomic technologies has revolutionized the current comprehension of biological processes underlying health and disease. However, now is the time to adopt these new technologies to improve human health, thus converting this information into reliable biomarkers. This endeavor should be focused on improving methodologies to analyze gene methylation, histone modifications and microRNAs. Ideally, epigenetic biomarkers should be robust, routine, accurate and inexpensive in order to provide better information for patient diagnosis, prognosis, stratification and treatment monitoring. Here we describe some challenges and provide strategies to improve the adoption of epigenetic biomarkers into clinical routine. Furthermore, we summarize the recommended properties for clinical epigenetic biomarkers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据